The Interim Sub-analysis from APEX Part 1+2 Studies; Efficacy and Safety of Dimethyl Fumarate in Treatment-naive Japanese Patients with Relapse-remitting MS

被引：0
|
作者：
Mori, M. [1 ]
Ohashi, T. [2 ]
Onizuka, Y. [3 ]
Hiramatsu, K. [3 ]
Hase, M. [3 ,4 ]
Yun, J. [4 ]
Torii, S. [3 ]
机构：
[1] Chiba Univ, Grad Sch Med, Dept Neurol, Chiba, Japan
[2] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Neurol, Chiba, Japan
[3] Biogen Japan Ltd, Tokyo, Japan
[4] Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-43
引用
收藏
页码：456 / 457
页数：2
相关论文
共 33 条
  • [1] Safety of Dimethyl Fumarate in Japanese Patients with Relapse-remitting MS for 72 Weeks in the APEX Part 1 and Part 2 Studies
    Ochi, H.
    Niino, M.
    Onizuka, Y.
    Hiramatsu, K.
    Hase, M.
    Yun, J.
    Torii, S.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 456 - 456
  • [2] Efficacy and Safety of Dimethyl Fumarate in Japanese MS Patients Who had the History of Treatment with Fingolimod: APEX Part 1+2 Interim Analysis
    Yokoyama, K.
    Nakahara, J.
    Onizuka, Y.
    Hiramatsu, K.
    Hase, M.
    Yun, J.
    Torii, S.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 457 - 458
  • [3] Efficacy and safety of dimethyl fumarate in treatment-naive Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study
    Mori, Masahiro
    Ohashi, Takashi
    Onizuka, Yasuhiro
    Hiramatsu, Katsutoshi
    Hase, Masakazu
    Yun, Jang
    Matta, Andre
    Torii, Shinichi
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2019, 5 (02)
  • [4] Efficacy and safety of delayed-release dimethyl fumarate in treatment-naive Japanese patients with relapsing-remitting multiple sclerosis: A post-hoc subgroup analysis of the apex study
    Mori, M.
    Ohashi, T.
    Onizuka, Y.
    Hiramatsu, K.
    Hase, M.
    Yun, J.
    Ling, Y.
    Torii, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 795 - 796
  • [5] SAFETY AND EFFICACY OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE IN TREATMENT-NAIVE JAPANESE PATIENTS WITH HIV-1 INFECTION
    Yajima, K.
    Yagura, H.
    Yukawa, S.
    Hirota, K.
    Ikuma, M.
    Kasai, D.
    Watanabe, D.
    Nishida, Y.
    Uehira, T.
    Shirasaka, T.
    SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A237 - A237
  • [6] Safety and Efficacy of Delayed-release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from Asia-Pacific and Other Countries: Interim Analysis of the APEX Extension Study
    Saida, Takahiko
    Yamamura, Takashi
    Kondo, Takayuki
    Yun, Jang
    Li, Jie
    Forsythe, Beverley
    Sheikh, Sarah, I
    Zhu, Bing
    NEUROLOGY, 2017, 88
  • [7] Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the Phase 3 EVOLVE-MS-1 Study
    Singer, B. A.
    Drulovic, J.
    Chen, H.
    Lyons, J.
    Then Bergh, F.
    Negroski, D.
    Kapadia, S.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 619 - 620
  • [8] Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 evolve-ms-1 study
    Wray, S.
    Singer, B.
    Drulovic, J.
    Chen, H.
    Hanna, J.
    Lyons, J.
    Bergh, F. Then
    Negroski, D.
    Kapadia, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 214 - 215
  • [9] Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
    Naismith, Robert T.
    Wolinsky, Jerry S.
    Wundes, Annette
    LaGanke, Christopher
    Arnold, Douglas L.
    Obradovic, Dragana
    Freedman, Mark S.
    Gudesblatt, Mark
    Ziemssen, Tjalf
    Kandinov, Boris
    Bidollari, Ilda
    Lopez-Bresnahan, Maria
    Nangia, Narinder
    Rezendes, David
    Yang, Lili
    Chen, Hailu
    Liu, Shifang
    Hanna, Jerome
    Miller, Catherine
    Leigh-Pemberton, Richard
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (13) : 1729 - 1739
  • [10] Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the Phase 3 EVOLVE-MS-1 study
    Bergh, F. Then
    Singer, B. A.
    Drulovic, J.
    Bidollari, I.
    Chen, H.
    Englishby, R.
    Hanna, J.
    Kandinov, B.
    Lopez-Bresnahan, M.
    Leigh-Pemberton, R.
    Miller, C.
    Mokliatchouk, O.
    Shafer, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 861 - 862
1234